Charles Schwab Investment Management Inc. Purchases 125,620 Shares of Integra LifeSciences Holdings Co. (NASDAQ:IART)

Charles Schwab Investment Management Inc. grew its position in shares of Integra LifeSciences Holdings Co. (NASDAQ:IART) by 15.3% in the 3rd quarter, according to the company in its most recent 13F filing with the SEC. The fund owned 944,282 shares of the life sciences company’s stock after purchasing an additional 125,620 shares during the quarter. Charles Schwab Investment Management Inc. owned about 1.22% of Integra LifeSciences worth $17,158,000 as of its most recent SEC filing.

Several other hedge funds have also recently added to or reduced their stakes in the company. CWM LLC raised its holdings in Integra LifeSciences by 50.8% during the 2nd quarter. CWM LLC now owns 1,262 shares of the life sciences company’s stock worth $37,000 after purchasing an additional 425 shares during the last quarter. Blue Trust Inc. increased its stake in shares of Integra LifeSciences by 100.5% in the 2nd quarter. Blue Trust Inc. now owns 886 shares of the life sciences company’s stock valued at $26,000 after acquiring an additional 444 shares in the last quarter. Zurcher Kantonalbank Zurich Cantonalbank increased its stake in shares of Integra LifeSciences by 7.5% in the 2nd quarter. Zurcher Kantonalbank Zurich Cantonalbank now owns 14,454 shares of the life sciences company’s stock valued at $421,000 after acquiring an additional 1,010 shares in the last quarter. KBC Group NV increased its stake in shares of Integra LifeSciences by 65.2% in the 3rd quarter. KBC Group NV now owns 2,839 shares of the life sciences company’s stock valued at $52,000 after acquiring an additional 1,120 shares in the last quarter. Finally, Allspring Global Investments Holdings LLC increased its stake in shares of Integra LifeSciences by 58.0% in the 2nd quarter. Allspring Global Investments Holdings LLC now owns 4,662 shares of the life sciences company’s stock valued at $136,000 after acquiring an additional 1,711 shares in the last quarter. Institutional investors own 84.78% of the company’s stock.

Wall Street Analysts Forecast Growth

IART has been the subject of several research analyst reports. Morgan Stanley initiated coverage on shares of Integra LifeSciences in a research note on Monday, December 2nd. They issued an “underweight” rating and a $20.00 price objective for the company. Truist Financial lowered their price objective on shares of Integra LifeSciences from $26.00 to $21.00 and set a “hold” rating for the company in a research note on Monday, October 14th. BTIG Research upgraded shares of Integra LifeSciences from a “sell” rating to a “neutral” rating in a research note on Monday, October 7th. Bank of America decreased their price target on shares of Integra LifeSciences from $26.00 to $18.00 and set an “underperform” rating for the company in a research note on Monday, October 7th. Finally, Citigroup boosted their price target on shares of Integra LifeSciences from $16.00 to $22.00 and gave the company a “sell” rating in a research note on Tuesday, November 5th. Three research analysts have rated the stock with a sell rating, five have given a hold rating and one has assigned a buy rating to the company. According to data from MarketBeat.com, the stock currently has a consensus rating of “Hold” and an average target price of $23.00.

Integra LifeSciences Stock Performance

NASDAQ IART opened at $24.10 on Friday. Integra LifeSciences Holdings Co. has a 1 year low of $16.81 and a 1 year high of $45.42. The company has a debt-to-equity ratio of 0.79, a current ratio of 1.20 and a quick ratio of 0.73. The firm has a market cap of $1.86 billion, a price-to-earnings ratio of -267.75, a PEG ratio of 0.82 and a beta of 1.15. The company has a fifty day moving average price of $21.44 and a 200-day moving average price of $23.88.

Integra LifeSciences (NASDAQ:IART) last posted its earnings results on Monday, November 4th. The life sciences company reported $0.41 earnings per share (EPS) for the quarter, topping the consensus estimate of $0.39 by $0.02. Integra LifeSciences had a negative net margin of 0.42% and a positive return on equity of 12.35%. The firm had revenue of $380.80 million during the quarter, compared to analyst estimates of $375.81 million. During the same quarter in the prior year, the business posted $0.76 EPS. The business’s revenue was down .4% compared to the same quarter last year. As a group, equities research analysts predict that Integra LifeSciences Holdings Co. will post 2.45 EPS for the current fiscal year.

Insider Transactions at Integra LifeSciences

In related news, EVP Michael J. Mcbreen sold 1,700 shares of the stock in a transaction dated Monday, December 2nd. The shares were sold at an average price of $24.16, for a total transaction of $41,072.00. Following the completion of the transaction, the executive vice president now owns 56,182 shares in the company, valued at approximately $1,357,357.12. This represents a 2.94 % decrease in their ownership of the stock. The transaction was disclosed in a filing with the Securities & Exchange Commission, which can be accessed through this link. Company insiders own 3.10% of the company’s stock.

About Integra LifeSciences

Integra LifeSciences Holdings Corporation manufactures and sells surgical instruments, neurosurgical products, and wound care products for use in neurosurgery, neurocritical care, and otolaryngology. It operates in two segments, Codman Specialty Surgical and Tissue Technologies. The company offers neurosurgery and neuro critical care products, including tissue ablation equipment, dural repair products, cerebral spinal fluid management devices, intracranial monitoring equipment, and cranial stabilization equipment; and surgical headlamps and instrumentation, as well as after-market services.